Literature DB >> 7912027

Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease.

D W Dickson1, M L Schmidt, V M Lee, M L Zhao, S H Yen, J Q Trojanowski.   

Abstract

Ubiquitin-immunoreactive dystrophic neurites in the CA2/3 region of the hippocampus are characteristic of diffuse Lewy body disease (DLBD). The origin of dystrophic CA2/3 neurites is unknown, but their extent correlates with the number of cortical Lewy bodies (LBs). To examine the molecular composition of these lesions, hippocampal sections were obtained at postmortem from cases of DLBD, Parkinson's disease and Alzheimer's disease. The tissue samples were fixed in a variety of fixatives and immunostained with antibodies to ubiquitin, ubiquitin C-terminal hydrolase (PGP9.5), neurofilament protein subunits, tau protein, paired helical filaments and tyrosine hydroxylase (TH). In addition to being ubiquitin positive, both cortical LBs and CA2/3 dystrophic neurites were positive with a neurofilament monoclonal antibody (RM032) and PGP9.5; however, fewer lesions were detected with these antibodies compared to ubiquitin immunocytochemistry. The dystrophic CA2/3 neurites were not stained with antibodies to tau proteins, paired helical filaments or TH. Absence of TH immunoreactivity suggests that CA2/3 neuritic processes are not derived from brain stem dopaminergic afferents to the hippocampus. Since CA2/3 neurites are immunologically similar to cortical LB, the pathogenesis of these lesions may be similar. Characterization of dystrophic CA2/3 neurites and cortical LBs may clarify how these lesions contribute to the emergence of dementia in DLBD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912027     DOI: 10.1007/bf00296742

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  50 in total

1.  Deposition of detergent-resistant neurofilaments into Lewy body fibrils.

Authors:  M S Pollanen; C Bergeron; L Weyer
Journal:  Brain Res       Date:  1993-02-12       Impact factor: 3.252

2.  Lewy bodies in tyrosine hydroxylase-synthesizing neurons of the human cerebral cortex.

Authors:  R O Kuljis; P Martín-Vasallo; N S Peress
Journal:  Neurosci Lett       Date:  1989-11-20       Impact factor: 3.046

3.  Lewy bodies of Parkinson's disease. Immune electron microscopic demonstration of neurofilament antigens in constituent filaments.

Authors:  M A Pappolla
Journal:  Arch Pathol Lab Med       Date:  1986-12       Impact factor: 5.534

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Antemortem diagnosis of diffuse Lewy body disease.

Authors:  H A Crystal; D W Dickson; J E Lizardi; P Davies; L I Wolfson
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

6.  Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly.

Authors:  R H Perry; D Irving; G Blessed; A Fairbairn; E K Perry
Journal:  J Neurol Sci       Date:  1990-02       Impact factor: 3.181

7.  Quantification of beta A4 protein deposition in the medial temporal lobe: a comparison of Alzheimer's disease and senile dementia of the Lewy body type.

Authors:  S M Gentleman; B Williams; M C Royston; R Jagoe; J Clinton; R H Perry; P G Ince; D Allsop; J M Polak; G W Roberts
Journal:  Neurosci Lett       Date:  1992-08-03       Impact factor: 3.046

8.  Amyloid angiopathy in diffuse Lewy body disease.

Authors:  E Wu; R B Lipton; D W Dickson
Journal:  Neurology       Date:  1992-11       Impact factor: 9.910

9.  Juvenile Parkinson's disease with widespread Lewy bodies in the brain.

Authors:  N Yoshimura; I Yoshimura; M Asada; S Hayashi; Y Fukushima; T Sato; H Kudo
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

10.  Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques.

Authors:  D W Dickson; H Crystal; L A Mattiace; Y Kress; A Schwagerl; H Ksiezak-Reding; P Davies; S H Yen
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

View more
  37 in total

1.  Glucocerebrosidase mutations in diffuse Lewy body disease.

Authors:  Kenya Nishioka; Owen A Ross; Carles Vilariño-Güell; Stephanie A Cobb; Jennifer M Kachergus; David M A Mann; Julie Snowden; Anna M T Richardson; David Neary; Christopher A Robinson; Alex Rajput; Spiridon Papapetropoulos; Deborah C Mash; Rajesh Pahwa; Kelly E Lyons; Zbigniew K Wszolek; Dennis W Dickson; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2011-01       Impact factor: 4.891

2.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.

Authors:  J E Galvin; K Uryu; V M Lee; J Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

3.  Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

Authors:  Omar El-Agnaf; Cassia Overk; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Nishant Vaikath; Nour Majbour; Seung-Jae Lee; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2017-05-02       Impact factor: 5.996

4.  Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer's disease.

Authors:  R McShane; K Gedling; M Reading; B McDonald; M M Esiri; T Hope
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-08       Impact factor: 10.154

5.  Loss of Brain Norepinephrine Elicits Neuroinflammation-Mediated Oxidative Injury and Selective Caudo-Rostral Neurodegeneration.

Authors:  Sheng Song; Lulu Jiang; Esteban A Oyarzabal; Belinda Wilson; Zibo Li; Yen-Yu Ian Shih; Qingshan Wang; Jau-Shyong Hong
Journal:  Mol Neurobiol       Date:  2018-07-27       Impact factor: 5.590

6.  Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations.

Authors:  Hiroshige Fujishiro; Akiko Yamashita Imamura; Wen-Lang Lin; Hirotake Uchikado; Margery H Mark; Lawrence I Golbe; Katerina Markopoulou; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Am J Neurodegener Dis       Date:  2013-11-29

7.  Amygdala pathology in Parkinson's disease.

Authors:  H Braak; E Braak; D Yilmazer; R A de Vos; E N Jansen; J Bohl; K Jellinger
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

8.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

9.  Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia.

Authors:  M G Martinoli; J Q Trojanowski; M L Schmidt; S E Arnold; T M Fujiwara; V M Lee; H Hurtig; J P Julien; C Clark
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

10.  Dystrophic serotonergic axons in neurodegenerative diseases.

Authors:  Efrain C Azmitia; Ralph Nixon
Journal:  Brain Res       Date:  2008-04-07       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.